The funds will be used for the development of laboratory animal resource bases and laboratories
Laboratory animal research service provider Lingfu Bio (Chinese: 灵赋生物) recently closed a pre-Series A financing round of more than CNY 200 million (USD 30.52 million) led by China Life Equity Investment and Legend Capital; Chang Development, Puhua Capital, Safe Pharmaceutical also took part. Probe Capital served as financial advisor.
Previously, the company had made nearly 50 million yuan in its angel funding round.
Beijing Lingfu Biotechnology is co-incubated in 2021 by several well-known companies and expert teams in the laboratory animal industry such as Safe Pharmaceutical and RenGene Biotech. It is committed to becoming the leading scientific research service provider in China enabling innovation in life sciences by integrating the whole industrial chain of laboratory animals, animal models and scientific research services. with high added value.
With a team of industry experts, as well as high-quality animal resource guarantee capabilities, large animal model service capabilities and scientific research service technology, Lingfu Bio has the potential to to be the next giant in the laboratory animal industry.
At present, Lingfu Bio has deployed the Yangtze River Delta beagle and marmoset experimental animal resource base, Hainan cynomolgus monkey and minipig experimental animal resource base, which are used for breeding the main experimental animals, conservation breeding, import substitution and the creation of a high-quality industrial chain.
It should be noted that the technical team of the company has strong technical strength in animal disease model modeling and has rich experience in gene editing modeling and surgical modeling, especially in the field of large animal modeling.
“The demand for laboratory animals and model animals continues to grow rapidly in recent years, while the production capacity of large model animals in China is relatively scarce. We expect Lingfu Bio to quickly cover the entire industry chain and become the most comprehensive supplier of high-quality experimental animal resources and featured animal models in China,” said Wang Jianfei, General Manager of Legend. Capital.
Lingfu Bio’s main competitors are Slac Laboratory Animal, Gem Pharmatech (688046:SH), HFK Bio and Shanghai Model Organisms.